Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

25.10.2021 | short review

Best of ASCO 2021—bladder cancer

Zeitschrift:
memo - Magazine of European Medical Oncology
Autoren:
MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Three trials presented at the meeting investigated the incorporation of immunotherapy into a multimodal bladder-sparing treatment approach. The results of these phase 2 trials are so far promising with most patients achieving complete remission (CR) and estimated bladder-intact disease-free survival (BIDFS) in these patients ranges between 73 and 88%. Additionally, the up to 5-year follow-up data from the KEYNOTE-052 study were discussed. The results confirm the efficacy of pembrolizumab as first-line monotherapy in cisplatin-ineligible patients with a programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel